Breast Cancer Cytochromes P450: Chemopreventive and/or Therapeutic Targets for Naturally Occurring Phytochemicals

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Estrogens are a primary risk factor for breast cancer.
• Cytochrome P450 enzymes (CYPs) are critical in estrogen synthesis, metabolism, and the formation of carcinogenic metabolites.
• CYP19 (aromatase) synthesizes estrogens, while CYP1B1 metabolizes them into DNA-damaging compounds.

Purpose of the Study:

• To review the effects of phytochemicals on major CYPs involved in estrogen metabolism.
• To identify potential therapeutic or chemopreventive agents for breast cancer.
• To discuss the modulation of CYP activity by flavonoids, stilbenes, and glucosinolate breakdown products.

Main Methods:

• Literature review of studies on phytochemicals and CYP enzymes.
• Analysis of in vitro and cell-based studies on CYP modulation.
• Focus on flavonoids (e.g., chrysin) and stilbenes as CYP inhibitors.

Main Results:

• Phytochemicals can inhibit or modulate the expression and activity of key CYPs (CYP19, CYP1B1).
• Chrysin is a notable CYP19 inhibitor, while stilbenes are effective CYP1B1 inhibitors.
• The effects of phytochemicals are often non-specific, necessitating further drug development.

Conclusions:

• Phytochemicals show promise in targeting estrogen metabolism pathways relevant to breast cancer.
• Further research is needed to develop specific and effective chemopreventive or therapeutic agents from these natural compounds.
• Understanding phytochemical-CYP interactions is crucial for breast cancer drug discovery.